Alkermes plc delivered a successful third quarter in 2025, marked by strong revenue growth and robust profitability, driven by solid performance across its commercial portfolio. The company reported total revenues of $394.2 million and GAAP net income of $82.8 million, with diluted GAAP earnings per share of $0.49. Alkermes also ended the quarter in a strong financial position with $1.14 billion in cash, cash equivalents, and total investments, and subsequently raised its financial outlook for the full year 2025.

Alkermes reported total revenue of $390.7 million and GAAP net income of $87.1 million in Q2 2025, driven by double-digit growth in LYBALVI, ARISTADA, and VIVITROL. The company maintained robust operating margins and reiterated its 2025 financial guidance.

Alkermes plc reported first quarter 2025 revenues of $306.5 million and GAAP net income of $22.5 million, with diluted GAAP earnings per share of $0.13. The company reiterated its 2025 financial expectations and highlighted progress in its ALKS 2680 development program.

Alkermes reported total Q4 2024 revenue of $430.0 million, up from $377.5 million in Q4 2023. Net income from continuing operations reached $145.7 million, while non-GAAP net income stood at $173.4 million. Adjusted EBITDA from continuing operations was $170.0 million. Revenue growth was driven by proprietary products, including VIVITROL, ARISTADA, and LYBALVI.

Alkermes reported third-quarter revenues of $378.1 million, with net sales of proprietary products increasing approximately 18% year-over-year. GAAP net income from continuing operations was $92.8 million, with diluted GAAP earnings per share from continuing operations of $0.56. The company reiterated its 2024 financial expectations.

Alkermes reported second quarter revenues of $399.1 million. GAAP net income from continuing operations was $94.7 million, with diluted GAAP earnings per share from continuing operations of $0.55. The company reiterated its 2024 financial expectations.

Alkermes reported a solid first quarter in 2024 with total revenues of $350.4 million and GAAP net income from continuing operations of $38.9 million. The company is advancing its strategic priorities, including LYBALVI's prescription growth and ALKS 2680's development.

Alkermes reported Q4 2023 financial results, with total revenues of $377.5 million. The company's proprietary product net sales increased year-over-year. GAAP net income for the quarter was $112.8 million. The company provided financial expectations for 2024, including generating a 30% EBITDA margin.

Alkermes reported Q3 2023 financial results with total revenues of $380.9 million and GAAP net income of $47.8 million. Net sales of proprietary products increased approximately 16% year-over-year. The company reiterated its financial expectations for full-year 2023 and expects to complete the separation of its oncology business in November 2023.

Alkermes reported strong Q2 2023 financial results, with total revenues of $617.4 million, including $248.4 million from the Janssen arbitration. Net sales of proprietary products increased by 21% year-over-year. The company reiterated its financial expectations for the full year 2023.

Alkermes plc reported first-quarter 2023 financial results, with total revenues of $287.6 million. The company saw strong performance in its proprietary product portfolio, with a 25% increase in net sales year-over-year. Alkermes is reiterating its financial expectations for 2023 and is progressing with the planned separation of its oncology business.

Alkermes plc reported Q4 2022 financial results, with total revenues of $304.7 million compared to $324.5 million for the same period in the prior year. GAAP net loss was $28.3 million, or a loss of $0.17 per share, while non-GAAP net income was $24.2 million, or $0.14 per share.

Alkermes reported Q3 2022 financial results, with total revenues of $252.4 million. Net sales of proprietary products were $199.4 million, reflecting growth in VIVITROL, ARISTADA, and LYBALVI. The company announced its intent to separate its neuroscience and oncology businesses and updated its financial expectations for full-year 2022.

Alkermes reported Q2 2022 financial results with total revenues of $276.2 million. Net sales of proprietary products were $190.8 million, driven by VIVITROL, ARISTADA, and LYBALVI. The company raised its financial expectations for full-year 2022.

Alkermes plc reported first quarter 2022 financial results, with total revenues of $278.5 million compared to $251.4 million for the same period in the prior year. The company reported a GAAP loss per share of $0.22 and non-GAAP earnings per share of $0.12. They reiterated their financial expectations for 2022.

Alkermes reported Q4 2021 revenues of $324.5 million and GAAP net income of $0.9 million, or $0.01 per share. Non-GAAP net income was $38.5 million, or $0.23 per share. The company provided financial expectations for 2022, reflecting a focus on proprietary products and continued operating efficiency.

Alkermes plc reported third-quarter 2021 financial results, with total revenues of $294.1 million, an 11% increase year-over-year. The company reported a GAAP net loss of $29.0 million, or $0.18 per share, and non-GAAP net income of $23.6 million, or $0.14 per share. They reiterated their financial expectations for 2021.

Alkermes plc reported a strong second quarter in 2021, with total revenues of $303.7 million, a 23% increase year-over-year. The company's performance was driven by commercial execution, with VIVITROL® and ARISTADA® demonstrating robust growth. Alkermes updated its full-year 2021 financial expectations based on this strong first-half performance.

Alkermes reported first quarter revenues of $251.4 million, reflecting solid performance of VIVITROL and ARISTADA. The company achieved a GAAP loss per share of $0.14 and non-GAAP earnings per share of $0.11. They reiterated their financial expectations for 2021.

Alkermes reported Q4 2020 revenues of $280.0 million and a GAAP net loss of $42.6 million, or a loss per share of $0.27. Non-GAAP net income was $16.5 million, or earnings per share of $0.10.

Alkermes plc reported Q3 2020 financial results with total revenues of $265.0 million. The company reported a GAAP net loss per share of $0.00 and non-GAAP earnings per share of $0.26. Strong commercial execution and disciplined expense management led to raised financial expectations for 2020.

Alkermes plc reported second quarter revenues of $247.5 million, GAAP net loss per share of $0.19 and diluted non-GAAP earnings per share of $0.06. The company is focused on commercial execution, aggressive development of pipeline programs, and efficient management of operating structure.

Alkermes reported Q1 2020 revenues of $246.2 million, primarily driven by a 30% year-over-year growth of proprietary product net sales. The company reported a diluted GAAP net loss per share of $0.24 and diluted non-GAAP earnings per share of $0.01. Due to COVID-19 uncertainties, the company withdrew its previously provided 2020 financial expectations.

Alkermes plc reported Q4 2019 financial results, with total revenues of $412.7 million compared to $315.8 million for the same period in the prior year. The company reported a GAAP net loss of $5.4 million, or $0.03 per share, and non-GAAP net income of $131.4 million, or $0.83 per share.